Who is sponsoring NCT03936504?

NCT03936504 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT03936504?

Interventions in NCT03936504: Control Group ：conventional exercise rehabilitation programs (CERP), Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP).

What condition does NCT03936504 study?

NCT03936504 studies Coronary Heart Disease, Chronic Coronary Syndrome.

Is NCT03936504 still recruiting?

NCT03936504 is currently status unknown. Last updated 9 December 2020.

Last reviewed 2020-12-09 · How we verify

NCT03936504

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Mechanism of TCCRP in Patients With Chronic Coronary Syndrome Under Fusion Cardiac Rehabilitation Model

Status unknown NA Last updated 9 December 2020

What this trial tests

NA trial testing Control Group ：conventional exercise rehabilitation programs (CERP) in Coronary Heart Disease in 100 participants. Status unknown.

Timeline

17 October 2019

Primary endpoint
30 July 2021

30 October 2021

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	100
Start date	17 October 2019
Primary completion	30 July 2021
Estimated completion	30 October 2021
Sites	3 locations across China

Drugs / interventions tested

Control Group ：conventional exercise rehabilitation programs (CERP)
Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)

Conditions studied

Coronary Heart Disease — all drugs for Coronary Heart Disease →
Chronic Coronary Syndrome — all drugs for Chronic Coronary Syndrome →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 80, any sex, with Coronary Heart Disease or Chronic Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multi-center, randomized controlled clinical study. It developed an innovative Tai Chi Cardiac Rehabilitation Program (TCCRP) for patients with chronic coronary syndrome (CCS) and evaluated the efficacy, acceptability and safety of TCCRP on patients with CCS in order to explore the possible mechanism of its feasibility.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and effectiveness of a Tai Chi-based cardiac rehabilitation programme for chronic coronary syndrom patients: study protocol for a randomised controlled trial.
Ma J, Zhang JW, Li H, Zhao LS, et al · · 2020 · cited 9× · PMID 32624473 · DOI 10.1136/bmjopen-2019-036061
Effects of a Tai Chi rehabilitation program implemented using a hybrid online and offline mode on oxidative stress and inflammatory responses in patients with coronary heart disease: a randomized controlled trial.
Cui M, Wei Q, Li Y, Liu M, et al · · 2024 · cited 3× · PMID 38827614 · DOI 10.3389/fpubh.2024.1369675
Evaluating the Effectiveness of a Hybrid Tai Chi Cardiac Rehabilitation Programme for Psychological Stress Reduction and Oxidative Stress in Patients With Chronic Coronary Syndrome: A Randomized Controlled Trial.
Cui M, Li C, Li Y, Chen Z, et al · · 2025 · cited 1× · PMID 40922118 · DOI 10.1002/smi.70088
Tai Chi as a mind-body exercise modulates endothelial function in coronary artery disease: A randomized clinical trial.
Li Y, Li C, Wen J, Cui M, et al · · 2025 · cited 1× · PMID 40553955 · DOI 10.1016/j.ctim.2025.103201

Verify or expand the search:

Other recruiting trials for Coronary Heart Disease

Currently open trials in the same condition.

NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03936504 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 9 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03936504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing